123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy

Antonini, Angelo; Benti, Riccardo; Notaris, Roberta De; Tesei, Silvana; Zecchinelli, Anna; Sacilotto, Giorgio; Meucci, N.; Canesi, Margherita; Mariani, Claudio; Pezzoli, Gianni; Gerundini, Paolo

doi:10.1007/s10072-003-0103-5

Cited by 129 publications

(87 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On early phase images, a decrease or increase of regional uptake is shown in MSA-P, MSA-C, PSP, and DLB groups compared with the IPD group. These findings generally correspond with several previous studies that have identified characteristic DAT binding of neurodegenerative parkinsonism [32][33][34] and glucose metabolism patterns with IPD, MSA, PSP, and DLB [11,23,26,27], respectively. NA not applicable…”

Section: Discussionsupporting

confidence: 92%

Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging

et al. 2012

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Dopamine transporter (DAT) imaging can demonstrate presynaptic dopaminergic neuronal loss in Parkinson's disease (PD). However, differentiating atypical parkinsonism (APD) from PD is often difficult. We investigated the usefulness of dual-phase F-18 FP-CIT positron emission tomography (PET) imaging in the differential diagnosis of parkinsonism. Methods Ninety-eight subjects [five normal, seven druginduced parkinsonism (DIP), five essential tremor (ET), 24 PD, 20 multiple system atrophy-parkinson type (MSA-P), 13 multiple system atrophy-cerebellar type (MSA-C), 13 progressive supranuclear palsy (PSP), and 11 dementia with Lewy bodies (DLB)] underwent F-18 FP-CIT PET. PET images were acquired at 5 min (early phase) and 3 h (late phase) after F-18 FP-CIT administration (185 MBq). Regional uptake pattern of cerebral and cerebellar hemispheres was assessed on early phase images and striatal DAT binding pattern was assessed on late phase images, using visual, quantitative, and statistical parametric mapping (SPM) analyses. Results Striatal DAT binding was normal in normal, ET, DIP, and MSA-C groups, but abnormal in PD, MSA-P, PSP, and DLB groups. No difference was found in regional uptake on early phase images among normal DAT binding groups, except in the MSA-C group. Abnormal DAT binding groups showed different regional uptake pattern on early phase images compared with PD in SPM analysis (FDR< 0.05). When discriminating APD from PD, visual interpretation of the early phase image showed high diagnostic sensitivity and specificity (75.4 % and 100 %, respectively). Regarding the ability to distinguish specific APD, sensitivities were 81 % for MSA-P, 77 % for MSA-C, 23 % for PSP, and 54.5 % for DLB. Conclusions Dual-phase F-18 FP-CIT PET imaging is useful in demonstrating striatal DAT loss in neurodegenerative parkinsonism, and also in differentiating APD, particularly MSA, from PD.

show abstract

Section: Discussionsupporting

confidence: 92%

Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging

et al. 2012

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…However, the putamen/caudate ratio is greater in APS than in PD, suggesting a more uniform dopamine depletion both in putamen and in caudate nucleus in APS patients; this result concurs with the previously discussed visual assessment. Two more studies verify that there is more symmetric loss of dopaminergic nerve terminals in MSA [35] and in PSP [36] compared to PD. This finding could depend on higher severity of clinical symptoms in APS patients at the time of the first clinical evaluation.…”

Section: Datscanmentioning

confidence: 89%

The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes

et al. 2015

View full text Add to dashboard Cite

The aim of the study was to compare the efficacy of olfactory testing and presynaptic dopamine imaging in diagnosing Parkinsons disease (PD) and atypical parkinsonian syndromes (APS); to evaluate if the combination of these two diagnostic tools can improve their diagnostic value. A prospective investigation of 24 PD patients, 16 APS patients and 15 patients with non-parkinsonian syndromes was performed during an 18-month period. Single photon emission computed tomography with the presynaptic radioligand I-123-FP-CIT (DaTSCAN (R)) and olfactory testing with the Brief 12-item Smell Identification Test (B-SIT) were performed in all patients. DaTSCAN was analysed semi-quantitatively, by calculating two different striatal uptake ratios, and visually according to a predefined ranking scale. B-SIT score was significantly lower for PD patients, but not significantly different between APS and non-parkinsonism. The visual assessment of DaTSCAN had higher sensitivity, specificity and diagnostic accuracy compared to olfactory testing. Most PD patients (75 %) had visually predominant dopamine depletion in putamen, while most APS patients (56 %) had visually severe dopamine depletion both in putamen and in caudate nucleus. The combination of DaTSCAN and B-SIT led to a higher rate of correctly classified patients. Olfactory testing can distinguish PD from non-parkinsonism, but not PD from APS or APS from non-parkinsonism. DaTSCAN is more efficient than olfactory testing and can be valuable in differentiating PD from APS. However, combining olfactory testing and DaTSCAN imaging has a higher predictive value than these two methods separately.

Funding Agencies|Ostergotland County Council (ALF); Swedish Parkinsons Foundation

show abstract

“…On the contrary, in PSP DAT imaging (putamen-to-caudate ratio) suggests a more uniform involvement of dopamine nerve terminals in both caudate nucleus and putamen 29 . In Fig 3 we highlight an illustrative brain SPECT imaging using TRODAT-1 as the radiopharmaceutical in a PSP-P subject matched for age and gender to a healthy control subject.…”

Section: Molecular Imaging (Dopaminergic Binding Sites)mentioning

confidence: 92%

Progressive supranuclear palsy: new concepts

Barsottini

Felı́cio

Aquino

et al. 2010

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Progressive supranuclear palsy (PSP) is a distinctive form of neurodegenerative disease which affects the brainstem and basal ganglia. Patients present supranuclear ophthalmoplegia, postural instability and mild dementia. PSP is defined neuropathologically by the accumulation of neurofibrillary tangles in the subthalamic nucleus, pallidum, red nucleus, substantia nigra, striatum, pontine tegmentum, oculomotor nucleus, medulla and dentate nucleus. Over the last decade many lines of investigations have helped refine PSP in many aspects and it is the purpose of this review to help neurologists identify PSP, to better understand its pathophysiology and to provide a more focused, symptom-based treatment approach. Key words: progressive supranuclear palsy, atypical parkinsonism, tauopathy.Paralisia supranuclear progressiva: conceitos atuais RESUMO A paralisia supranuclear progressiva (PSP) é uma doença neurodegenerativa, que afeta principalmente o tronco cerebral e os núcleos da base. O quadro clínico se caracteriza por oftalmoparesia supranuclear, instabilidade postural e demência . Do ponto de vista anátomo-patológico, a PSP se caracteriza por acúmulo de emaranhados neurofibrilares no núcleo subtalâmico, globo pálido, núcleo rubro, substância negra, estriado, tegumento da ponte, núcleos oculomotores, bulbo e núcleo denteado. Nas últimas décadas, muitas linhas de pesquisa têm colaborado para redefinir a PSP em muitos aspectos. Os objetivos dessa revisão são auxiliar o neurologista geral na identificação da doença, compreensão da sua fisiopatologia, além de apresentar alternativas para seu tratamento sintomático. Palavras-chave: paralisia supranuclear progressiva, parkinsonismo atípico, taupatias.

show abstract

123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy

Cited by 129 publications

References 7 publications

Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging

Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging

The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes

Progressive supranuclear palsy: new concepts

Contact Info

Product

Resources

About